

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|---------------------------|----------------------|----------------------|-------------------------|------------------|
| 09/875,520 | 06/06/2001 | Phillip R. Hawkins | PF-0059-5 CON | 6922 |
| 22428 75 | 590 06/09/2004 | | EXAMINER | |
| FOLEY AND LARDNER | | | MURPHY, JOSEPH F | |
| SUITE 500 3000 K STREE | TNW | | ART UNIT | PAPER NUMBER |
| | WASHINGTON, DC 20007 | | 1646 | • |
| | | | DATE MAILED: 06/09/2004 | |

Please find below and/or attached an Office communication concerning this application or proceeding.

| | Application No. | Applicant(s) | | | | |
|---|--------------------------------|----------------------|--|--|--|--|
| Interview Summary | 09/875,520 | HAWKINS ET AL. | | | | |
| interview Summary | Examiner | Art Unit | | | | |
| | Joseph F Murphy | 1646 | | | | |
| All participants (applicant, applicant's representative, PTO | personnel): | | | | | |
| (1) <u>Joseph F Murphy</u> . | (3) | | | | | |
| (2) <u>Lauren Wendt</u> . | (4) | | | | | |
| Date of Interview: <u>08 June 2004</u> . | | | | | | |
| Type: a)⊠ Telephonic b)⊡ Video Conference c)⊡ Personal [copy given to: 1)⊡ applicant 2 | 2)⊡ applicant's representative | · •] | | | | |
| Exhibit shown or demonstration conducted: d) Yes e D No. If Yes, brief description: | | | | | | |
| Claim(s) discussed: | | | | | | |
| Identification of prior art discussed: | | | | | | |
| Agreement with respect to the claims f) was reached. g | ı)☐ was not reached. h)☐ N | I/A. | | | | |
| Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: <u>Discussed amendment of claim 28 to recite a function for the target protein, e.g.inhibition of PLA2 activity, and amending the claim to recite that the target protein is 80% identical to SEQ ID NO: 2. Also discussed rejoinder of claims 29, 43-44, addition of a specific disease to claim 29, and addition of a step to claim 44 wherein the AB-protein conjugate is isolated.</u> | | | | | | |
| (A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.) | | | | | | |
| THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet. | | | | | | |
| no felly is necessary. G. 8.07 | | | | | | |
| | | | | | | |
| | | | | | | |
| Examiner Note: You must sign this form unless it is an | h | and we if you it and | | | | |
| Attachment to a signed Office action. | ⊨xanyıner s sıgr | nature, if required | | | | |